pemigatinib
incyte
['pemigatinib']
good pan-cancer activity of pemigatinib with orrs of 26.5% in fusions and 9.4% in snvs. zero activity with concurrent mapk pathway mutations at baseline. #aacr23 
Director, Kabara Cancer Research Institute; Dr. Jon & Betty Kabara Endowed Chair in Precision Oncology. Gundersen Medical Foundation. Opinions are my own.